Utilizing spinal cord injury stratification during classification for allocation of para surfing sport classes.

OBJECTIVES: The purpose of this study was to determine which stratification (anatomical versus functional) forms a better construct for classification of para surfers with spinal cord injury; to assess the groupings of these para surfers; and to evaluate the strength of association between manual muscle testing and surfing performance. DESIGN: Cross-sectional. METHODS: Archived data from classification records including demographics, spinal cord injury levels, trunk strength, and limb strength were compared to judged wave scores and competition rankings. RESULTS: Participants (n = 70, male n = 56; female n = 14) met inclusion criteria and were classified into Para Surfing Kneeling (n = 9); Sit (n = 11); Prone 1 (n = 25); and Prone 2 (n = 25) sport classes. Reliability statistics showed that functional grouping (Cronbach's α = 0.759) is better grouped with strength testing and rankings compared to anatomical grouping (Cronbach's α = 0.721). Under exploratory factor analysis with 2 fixed components, based on the factor loadings (rank and strength) functional stratification (0.978) is better aligned compared to anatomical stratification (0.785) for grouping of surfers. Further, the association and impact of strength with functional spinal cord level stratification were confirmed using regression analysis (chi-square of 74.06 with p-value <.0001). CONCLUSIONS: Trunk and limb strengths have been shown to influence wave riding performance in surfers with spinal cord injury. Surfers with spinal cord injury can equitably be classified into one of the four para surfing sport classes. The use of functional stratification of spinal cord injury with trunk and limb strengths should be considered as an integral component in para surfing athlete sport classification.

Development of evidence-based classification for para surfers with physical impairments: A narrative review.

The sport of competitive para surfing is growing internationally without established classification procedures. A classification structure is essential for equitable sport competition and worldwide sport progression. This narrative review summarizes the existing knowledge on Paralympic classification and surfing biomechanics. Its primary purpose is to describe the development of an evidence-based para surfing classification structure that follows the International Paralympic Committee (IPC) Classification Code. Two databases-PubMed and Google Scholar-were searched for three themes: "Paralympic classification", "performance determining factors in surfing", and "impact of impairments on surf performance". The IPC Classification Code and IPC regulations were obtained from the IPC website and official publications. Seventy-six relevant articles were utilized to guide the design of this preliminary para surfing classification structure. A conceptual framework on athlete characteristics, adaptive sport characteristics, and use of equipment is presented to build the essential knowledge base for continual growth of para surfing. This classification structure and conceptual framework will support para surfing sport expansion and help pave the way for its inclusion in the Paralympic Games.

COVID-19 Vaccine Uptake Among College Students at a Midwest University.

COVID-19 is responsible for over 750,000 Americans deaths. Despite efforts to vaccinate, many college students are hesitant. Hesitancy has hindered efforts to achieve high COVID-19 vaccination rates. Students at a Midwest university completed an online survey. Questions included COVID-19 vaccination intent and behavior. Over 1600 students participated. Half reported being vaccinated. Of those not vaccinated, 49% did not intend to get vaccinated, and 22% were undecided. Reasons for hesitancy included not trusting the vaccine was fully tested (85%), fear of potential side effects (78%), not trusting the vaccine is safe (72%), not trusting the US government (61%), and having read negative reports from the media about the vaccine (60%). Additionally, students were concerned the vaccine was not safe (B = - 0.902; 95% Χ2 = 11.68; p = 0.001) and that it could not protect them from COVID-19 (B = - 0.834; Χ2 = 12.43; p < 0.001). Students' religious beliefs (B = - 1.245; Χ2 = 4.61; p = 0.032) and having unvaccinated family members (B = - 0672; Χ2 = 11.50; p = 0.001) also contributed to intention not to receive the vaccine. Unexpectedly, students reporting fear of potential side effects (B = 1.26; Χ2 = 12.86; p < 0.001) were significantly more likely to indicate intention to get vaccinated than students who did not report this fear. College students may be more hesitant to receive the vaccination than others. Targeted messaging addressing concerns/fears may be a way to influence those who are hesitant to receive the COVID-19 vaccination.

Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis.

AIMS: JNJ-64179375 (hereafter JNJ-9375) is a first-in-class, highly specific, large molecule, exosite 1 thrombin inhibitor. In preclinical studies, JNJ-9375 demonstrated robust antithrombotic protection with a wider therapeutic index when compared to apixaban. The purpose of the present study was to examine for the first time the antiplatelet, anticoagulant and antithrombotic effects of JNJ-9375 in a translational model of ex vivo human thrombosis. METHODS AND RESULTS: Fifteen healthy volunteers participated in a double-blind randomized crossover study of JNJ-9375 (2.5, 25, and 250 µg/mL), bivalirudin (6 µg/mL; positive control), and matched placebo. Coagulation, platelet activation, and thrombus formation were determined using coagulation assays, flow cytometry, and an ex vivo perfusion chamber, respectively.JNJ-9375 caused concentration-dependent prolongation of all measures of blood coagulation (prothrombin time, activated partial thromboplastin time, and thrombin time; P < 0.001 for all) and agonist selective inhibition of thrombin (0.1 U/mL) stimulated platelet p-selectin expression (P < 0.001) and platelet-monocyte aggregates (P = 0.002). Compared to placebo, JNJ-9375 (250 µg/mL) reduced mean total thrombus area by 41.1% (95% confidence intervals 22.3 to 55.3%; P < 0.001) at low shear and 32.3% (4.9 to 51.8%; P = 0.025) at high shear. Under both shear conditions, there was a dose-dependent decrease in fibrin-rich thrombus (P < 0.001 for both) but not platelet-rich thrombus (P = ns for both). CONCLUSION: Exosite 1 inhibition with JNJ-9375 caused prolongation of blood coagulation, selective inhibition of thrombin-mediated platelet activation, and reductions in ex vivo thrombosis driven by a decrease in fibrin-rich thrombus formation. JNJ-9375 represents a novel class of anticoagulant with potential therapeutic applications.

Community-Based Needs Assessment of Neurodevelopment, Caregiver, and Home Environment Factors in Young Children Affected by HIV in Lima, Peru.

BACKGROUND: In many resource-poor settings such as Peru, children affected by HIV have a high prevalence of neurodevelopmental delays (NDDs) and remain excluded from adequate treatment. METHODS: Community health workers (CHWs) administered NDD screening instruments to assess child development and associated caregiver and household factors in 14 HIV-affected parent-child dyads. Focus group discussion with caregivers was conducted to explore their needs and behaviors around early child stimulation and to assess their perceptions of the screening experience. RESULTS: Over 70% of the children had abnormal classification in at least 1 (out of 5) developmental domains according to Ages and States Questionnaire-provided cutoff scores. Caregiver depression and stress were associated with abnormal development as were some parenting behavior factors. Knowledge about child development was low. Caregivers felt testing and discussing results with a CHW were very insightful. Reported caregiver behavior differed between caregivers with HIV-infected children and those with uninfected children. CONCLUSION: Taken together, these exploratory quantitative data suggest that parenting behaviors associated with low child development scores may be modifiable and that community-based testing is well received and informative to these HIV-infected caregivers.

Mayo Clinic Reduces Catheter-Associated Urinary Tract Infections Through a Bundled 6-C Approach.

The primary CAUTI reduction strategies of ensuring aseptic technique during catheter placement and reducing urinary catheter utilization were already in place at our institution. A multidisciplinary team approach, which entailed the use of QI methodology and engagement of frontline staff, resulted in the identification of additional strategies to reduce CAUTI. By implementing these strategies, we successfully reduced CAUTIs and have sustained this reduction through March 2016. The tools created during this project can be easily adapted for use at other institutions.

Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-ß1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants.

AIM: To evaluate the pharmacokinetics and safety of single intravenous doses of JNJ-54452840 infused over 1 minute in healthy male Japanese and Caucasian participants. JNJ-54452840 is a novel peptide for the treatment of chronic heart failure, with a proposed mechanism of action of binding interference and decreased production of anti-ß1-adrenergic receptor (anti-ß1-AR) antibodies, which stimulate the cardiac ß1-AR. METHODS: In this randomized, single-centre, double-blind, placebo-controlled, four-way crossover study, 32 male Japanese and Caucasian participants (16 in each group) received single intravenous doses of JNJ-54452840 20, 80 and 240 mg, and placebo, each separated by a ≥7-day washout period. Pharmacokinetics and safety were assessed predose and at specified timepoints for 24 h. Anti-ß1-AR antibodies were monitored. RESULTS: The mean JNJ-54452840 maximum observed plasma concentration (C max) and area under the concentration-time curve from time zero to infinity with extrapolation of the terminal phase (AUCinf) values increased linearly with dose, with rapid elimination in both groups. Dose proportionality criteria were not met between the 20 and 240 mg doses for both study cohorts. The median time to reach C max (T max) ranged from 1 to 5 minutes. The mean total systemic clearance after intravenous administration (CL), volume of distribution at steady state (V ss), mean residence time (MRT) and terminal half-life (T ½) values were similar for both groups. The mean T ½ values ranged from 5.9 to 26.1 min in a dose-dependent manner. The overall prevalence of antibodies was 9.4 % at baseline; antibodies not present at baseline developed in five Caucasians (15.6 %) but not in Japanese participants. One participant in each group experienced a serious thromboembolic event (pulmonary embolism, ischaemic stroke). CONCLUSION: JNJ-54452840 demonstrated similar pharmacokinetics in both groups. JNJ-54452840 was possibly immunogenic, and two participants reported thromboembolic serious adverse events. The relationship between these events and antibody formation is not known.

First International Workshopson Provocative Questions (PQ) in Cancer Research, October-November 2014, New Delhi, Bengaluru, and Thiruvananthapuram, India.

In 2011, the National Cancer Institute (NCI, USA) introduced the Provocative Questions (PQ) Initiative, a new approach allowing active researchers to define major unsolved or neglected problems in oncology unaddressed by existing funding. Last year, the U.S. NCI teamed up with the Indian Department of Biotechnology (DBT) to pilot the PQ approach in three cities in India. Workshop outcomes includedthe generation of fundable "PQs" (perplexing questions understudied by the international scientific community), as well as the identification of several non-PQ projects and research-related issues of importance to DBT and other Indian funding groups. The workshops clearly indicated the need to expand beyond crafting "PQs" when considering the best areas for research funding in international settings. Nonetheless, the first set of PQ workshops provided a forum to discuss key issues regarding cancer research in India, including the paucity of cancer research funding, and the lack of relevant human resource training and technology sharing platforms. Continued open debate between researchers, funders and policymakers will be essential to effectively strengthen the cancer research portfolio in India.

Accommodating intraocular lens implantation in an epikeratophakia patient.

We report a case of implantation of the Crystalens AT-45SE and AT-52SE intraocular lenses in a highly myopic patient who had bilateral epikeratophakia surgery 15 years previously. Lessons learned from the first eye were taken into consideration when selecting the dioptric power for the fellow eye. With secondary interventions and meticulous lens calculations, the final outcomes were excellent and equivalent, allowing the patient to achieve uncorrected distance and intermediate visual acuities of 20/25 and near visual acuity of 20/50 in both eyes. To our knowledge, this is the first reported case of accommodating lens implantation in an epikeratophakic eye.

Improving clinical research and cancer care delivery in community settings: evaluating the NCI community cancer centers program.

BACKGROUND: In this article, we describe the National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) pilot and the evaluation designed to assess its role, function, and relevance to the NCI's research mission. In doing so, we describe the evolution of and rationale for the NCCCP concept, participating sites' characteristics, its multi-faceted aims to enhance clinical research and quality of care in community settings, and the role of strategic partnerships, both within and outside of the NCCCP network, in achieving program objectives. DISCUSSION: The evaluation of the NCCCP is conceptualized as a mixed method multi-layered assessment of organizational innovation and performance which includes mapping the evolution of site development as a means of understanding the inter- and intra-organizational change in the pilot, and the application of specific evaluation metrics for assessing the implementation, operations, and performance of the NCCCP pilot. The assessment of the cost of the pilot as an additional means of informing the longer-term feasibility and sustainability of the program is also discussed. SUMMARY: The NCCCP is a major systems-level set of organizational innovations to enhance clinical research and care delivery in diverse communities across the United States. Assessment of the extent to which the program achieves its aims will depend on a full understanding of how individual, organizational, and environmental factors align (or fail to align) to achieve these improvements, and at what cost.